Biosimilar Naming: Hospira Says Retacrit, Nivestim Postmarket Reports Support One INN
Executive Summary
Hospira says 99% of Retacrit postmarket reports identified the product without the need for international non-proprietary name differentiation; WHO to consider biosimilar naming at its Oct. 22 meeting.